Tetratherix March Investor Presentation
Released
Released
Announcement PDF
Tetratherix
Investor
Presentation
March 2026
ASX: TTX ABN: 72 607 771 077
The evolving dynamics of the global healthcare system are demanding innovative and cost-effective biomaterials
Trends in healthcare delivery
Patients are increasingly demanding higher quality of care with a
particular focus on reducing recovery times and lower risk of
complications (e.g. infection, blood loss, pain) - which is also a driver
of increasing healthcare costs for patients and payers
Rising patient expectations
Increasing global healthcare spending and demand for healthcare
services is necessitating investment in cost-effective tools and
treatments, including those that can be delivered outside a traditional
hospital setting, to minimise burden on the healthcare system
Need for cost-effective, decentralised care
Why does the world need Tetratherix?
Introduction
These numbers are forecast to double
over the next 10 years
70m
Estimated 70 million US outpatient
procedures per year and increasing by
>6%
60% Nearly 60% of outpatients
are operated on in ASCs
2X
Orthopaedic, ophthalmology, urology
and neuro/pain are the main segments
being disrupted
Our Tetramatrix platform is best positioned to address the clinical demands that are central to the evolution
Minimally invasive
delivery
Water-based solution
injected through fine
gauge needle
Safe,
biocompatible
and bioresorbable
No foreign body reaction
upon application
Low cost, scalable
production
Non-labour intensive, low
cost and readily available
materials
Seamlessly
integrated into
existing workflows
No additional equipment
required
How does Tetramatrix help facilitate this shift?
Introduction
Tetramatrix
A biomaterial platform built with unique polymer programming akin to “medical Lego ” to
form implantable products to solve a wide range of clinical problems. The platform has built
products for 7 anatomical sites with 3 chemical entities derived from the core technology.
Intelligent
Modular
Biomimetic
Safe
The matrix has similar water content and mechanical properties to
natural tissue, and therefore is impervious to the body, helping heal
injuries or physically manipulating the body during surgical interventions.
Standard
of
care
Treated
with
our
platform
Inflammatory Fibrovascular (IFV)
Tissue ingrowth
Human Histological Evaluation
Tetramatrix™ platform technology is the world’s first biostealth fluid matrix
A decade of polymer programming has led to an ideal consistency & physical performance.
The material is an injectable fluid to avoid causing damage to the body during its application.
Using physiological temperature, material transitions into a 3D matrix.
Introduction
Due to the unique polymer programming of the material, once the matrix serves its
purpose, the material gradually and safely bioresorbs in the body with no impact locally or
systemically. Biocompatibility data from multiple clinical trials show no impact to internal organs
or blood markers.
Transparent
Opaque
12 weeks
Structure
Stability
5 minutes
Long-bone
Biomechanics
Eye tissue
Preclinical studies (equivalent to 5 litre product administration)
No effects on blood markers for internal functions of
liver, kidney and spleen
Fully resorbed and excreted from the body
Derived medical devices from the Tetramatrix™ platform technology span multiple
large franchises and significant near-term commercial opportunities
Franchises
Tissue Healing
Tissue Spacing
Bone Regeneration
Bone graft extender for
dental surgeries
Flowable bone graft
extender for orthopaedic
applications
Prostate Spacer for
radiation therapy
Spacer during
cataract surgeries
Intraoperative solution to reduce scar
formation after surgeries
An initial addressable
combined market of
$USD6.8B
$6.8B
*TAM Defined by 3 initial franchises only
Different clinical needs. Different market segments. Single Tetramatrix platform technology.
TM
The Tetramatrix biomaterial is our core ‘platform’ technology. We have completed the foundational safety, efficacy and manufacturing work which is
transferable across different clinical applications of the platform.
We will license the IP in a specific field to a leader in the segment. These partners complete the “final 20%” to turn the application into a clinical product.
We will then manufacture the product and supply at attractive unit economics to our industry leading partners who distribute it though their sales
channels.
We will enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.
Think of us like a software platform business...
Commercial model
Supply of
product at
scale
Licensing &
Milestone
Payments
1 2
A capital light model with compounding revenue
While we build our own production and R&D infrastructure, we avoid committing
capital on establishing multiple sales & distribution networks by utilising the
capabilities of our partners’ established teams.
Importantly, we operate in unison with our partners. Our high margin revenue
compounds over time by adding new partnerships and launching new products.
Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than,
traditional medtech companies. Therefore, our return profile is different and not built
on expectations of an eventual acquisition.
Avoided Sales &
Marketing Cost by
using partners’ in-
market infrastructure
Design Proof of Concept
Clinical
Validation
Regulatory
Approval
Go-to-Market
Income
Cost
Plateaued Cost
In TTX Model
Commercial model
This unique and attractive model is enabled by:
A platform technology that allows parallel developments
Advanced manufacturing with economies of scale
Partnerships with leading players who are motivated to
sell over a long time
A patient & deliberate strategy
An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.
Supported by complete IP coverage
Patent stack with 36 granted patents from 9 families of patent,
extending to 2044 & beyond and fully owned by Tetratherix
Introduction
R&D investment
at 39% of total
expenditure
Total $3.1m +160%
vs H1Fy25
61%
R&D
39%
R&D
39%
*R&D includes specific projects,
directly attributable staff,
laboratory costs, trademarks and
patents
Bone Regeneration
$2.0m
Tissue Healing
$0.7m
Tissue Spacing $0.1m
Pipeline $0.3m
+160% vs H1 FY25
FDA regulatory studies x 2
(Tegenix and TegenEOS)
Clinical trial for scar
prevention (TetraDerm)
Preclinical in AU/US
Tutelix clinical trial + BioOptix
preclinical
Derived medical devices from the Tetramatrix™ platform technology span multiple large
franchises and significant near-term commercial opportunities
Franchises
Tissue Healing
Tissue Spacing
Bone Regeneration
Bone graft extender for
dental surgeries
Flowable bone graft
extender for orthopaedic
applications
Prostate Spacer for
radiation therapy
Spacer during
cataract surgeries
Intraoperative solution to reduce scar
formation after surgeries
An initial addressable
combined market of
$USD6.8B* $6.8B
Same core technology,
same material and
interchangeable dataset
Tissue
Healing
Tissue
Spacing
Bone
Regeneration
Precision
Medicine
*TAM Defined by 3 initial franchises only
Expansion by Design: Transitioning from Three Pillars to a Four-Node Ecosystem
Introducing STEPP -
Tetratherix’s enabling vehicle
for novel delivery of
compounds
The STEPP project has been in stealth mode and under deep
development for more than 5 years, including global R&D studies with
several big pharma partners.
The Tetramatrix™ platform’s STEPP - the enabling vehicle for novel delivery of compounds
STEPP | Mode of Action for STEPP Drug Delivery
The polymer system is negatively charged and the presence of hydrophilic + hydrophobic groups within PNPHO create a protective micelle-like layer around biologics.
Biologics
PNPHO polymer
Dissolution of PNPHO and
the biologics in buffered
solutions at 4 ºC
Polymer encapsulation/
nanoparticle formation
around biologics (< 37ºC)
Biologics agglomeration
in the absence of PNPHO
polymer
+ Chitosan
TP035
No Carrier
BSA Semaglutide e-GFP mRNA
No Carrier
TP035 TP035
No Carrier
A unique protective layer around the cargo that means the
cargo doesn’t stick together or get ruined during delivery.
Because the cargo doesn’t stick together and ‘clump’, the
particle size is smaller for better transportation
Tetramatrix™ platform - vehicle enabling effective nasal delivery of compounds
STEPP | An Introduction
Controlled release of compounds
Nasal spray
STEPP
Carrier
Compound
Biological
1 Physical
2 Commercial
3
Our delivery system
facilitates sustained
release of cargo
STEPP has been
shown to reduce
enzymatic degradation
of incorporated cargo in
multiple applications
Allows unique routes
for systemic delivery
STEPP forms a
protective micelles
around incorporated
cargo to allow for
stability and protection
STEPP is a stabilising
agent for the cargo
STEPP retains the
cargo at the delivery
site
STEPP is simple to
incorporate with routine
manufacturing
STEPP is proprietary -
allowing a unique product
offering
STEPP may allow for
‘surprising synergies’ and
by extension - facilitates
new formulation patents
for off-patent candidates
STEPP Spray
The use of the carrier in different formulations allows direct spray with no nose or throat run off
STEPP | Physical Adhesion Is a Big Deal
The following example is with mRNA/LNP (global big pharma collaboration), representing a challenging test for nasal delivery and mucosa adhesion.
TP025+ Low coverage at the upper
regions
Nose runoff instantly after application
Collected solution
after spray
Nose runoff and product
wastage
Control (No Carrier)
The nose and throat runoff
affect the reproducibility of
the dosage without the
carrier system.
60% product
loss
The use of the carrier in different formulations allows direct spray with no nose or throat run off.
STEPP | Physical Adhesion Is a Big Deal
The following example is with mRNA/LNP (Global big pharma collaboration), representing a challenging test for nasal delivery and mucosa adhesion.
TP025+ Low coverage at the upper
regions
Nose runoff instantly after application
Collected solution
after spray
Nose runoff and product
wastage
Control (No Carrier)
The nose and throat runoff
affect the reproducibility of
the dosage without the
carrier system.
60% product
loss
No nose dripping
Upper regions coverage
With Carrier
Wide coverage and no nose-
and throat- runoff with the
carrier system.
STEPP delivers cargo and maintains activity of different cargos before & after administration
STEPP | Mode of Action for STEPP Drug Delivery
Different in vitro and in vivo preclinical studies have confirmed the potential of the
technology to deliver different compounds. STEPP controls the release of cargo and
allows both systemic and direct-to-brain delivery of different actives.
With Carrier
Insulin/GLP-1
1
Confirmation of stability
Confirmation of sustained release
Animal study to show delivery
mRNA/LNP
2
Confirmation of stability
Confirmation of sustained release
Confirmation of biological activity
post release
Analgesics &
Antibiotics
3
Confirmation of stability
Confirmation of sustained release
Confirmation of in vitro activity post
release
TP025+
TP035+
Free Active
TP020+
TP035+
Free Active
After incubation with aminopeptidase (AP) enzyme
Controlled release of active cargos (GLP-1 etc) in the
presence of the carrier. Free cargo displayed a burst
release, whereas with 25 mg/ml (TP025+) and 35 mg/ml
(TP035+) of PNPHO, the burst release is prevented.
The presence of the carrier system prevent the
degradation of the cargo in mucosa via enzymes.
These results suggest that the carrier can increase
the bioavailability of GLP-1 or other actives via nasal
delivery.
Inj Insulin Insulin Nasal TP035+ Nasal
0.0
0.2
0.4
0.6
0.8
1.0
Normalise
Brain:Serum
Insulin
Ratio
Continuous intelligence: real-world
evidence acquisition at the biological
frontier
Pioneers of ‘Pharma 2.0': Superpower is a
sophisticated US-based precision health company
that moves beyond traditional reactive medicine by
utilising an AI-driven ‘Test, Prescribe, Optimise’
model.
Data-Driven Patient Care: Their platform integrates
comprehensive biomarker tracking - including blood
panels and metabolic screening - to proactively
identify health issues and generate personalised
protocols that combine pharmaceuticals with lifestyle
interventions.
Strategic Market Access: The partnership utilises
an agile ‘compounding-first’ model, allowing
Tetratherix to start collecting real world evidence in
the US GLP-1 and peptide markets immediately
under existing regulatory frameworks.
Strong Financial & Consumer Backing:
Superpower is a highly capitalised partner backed by
US VC and high profile individuals. The health
platform currently has a significant waitlist of over
200,000 people.
The Partner The Agreement
Exclusive R&D Agreement: Tetratherix will receive
an exclusive licensing fee for the use of its technology
in the R&D fields of nasal drug delivery and the
subcutaneous delivery of select compounds. This fee
is structured as a annual payment of US$3m payable
on renewal by Supwerpower for up to 10 years.
Ongoing Polymer Sales: Beyond licensing, the
company will also generate revenue through the sale
of the Tetramatrix™ polymer. As Superpower scales
its customised product offerings, Tetratherix will act as
the primary supplier of this essential biostealth carrier.
Expedited Pathway to Revenue: This allows
Tetratherix to divert from the traditional, multi-year
pharmaceutical development cycles and generate
real world demand and an immediate channel to
commercialise assets like nasal GLP-1s - generating
revenue in FY26.
Real-World Evidence Generation: The partnership
serves as a high-scale, revenue-generating pilot that
provides direct access to real-world use evidence by
gathering patient insights on efficacy and tolerance.
The Opportunity
Unprecedented Market Scale: The global market for
GLP-1 agonists is currently the fastest-growing sector
in pharmaceutical history, projected to exceed $100b
by 2030. This opportunity extends into the broader
peptide and hormone replacement therapy markets,
where the shift toward quality of life treatments is
driving a wave of demand.
High-Value Comparable Benchmarks: The industry
is currently in a ‘delivery leadership’ arms race,
evidenced by multi-billion dollar acquisitions of carrier
technologies. Notable benchmarks include Novo
Nordisk’s $1.8b acquisition of Emisphere for its SNAC
oral delivery technology and Pfizer’s recent
investment in Metsera for its HALO delivery system.
The Delivery Holy Grail: While the efficacy of our
targets are well-established, the industry's primary
hurdle has shifted from the ‘active ingredient’ to the
‘delivery system’. Nasal delivery is considered the
holy grail because it offers the high efficacy of an
injection with the frictionless convenience of a spray,
potentially capturing the >15% of patients who
currently opt out of treatment due to needle fatigue or
phobia.
ASX: TTX ABN: 72 607 771 077
EXECUTION OF
THE STRATEGY
SINCE IPO
9 months after ASX listing - Efficient use of Funds and Strong Cash Position
#anchoredbyscience
Near Term Milestones
FY2026 FY2027
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
Cohort 2
Commenced
Year 1 Follow up for
Cohort 1 results
published
TetraDerm Cohort
3 Initiation
(Major Surgeries)
ONCOLOGY
DENTAL
Master Partnership
Agreement Execution
Supply and Licensing
Agreement Execution
FDA
Clearance
FDA Submission
New Facility Signed
and production begins
IGP Grant
Board
Restructure
ISO13485
surveillance
Audit
MDSAP
Stage 1
Audit
Primary End-
point Cohort 2
FDA Pre-submission
& Regulatory Pathway
BioOptix Licensing
Agreement
US / AU
Capital Raise
Preclinical Data
Read-out
Strategic Global
Partnership
FDA Pre-submission &
Regulatory Pathway
FDA Pre-submission/
Regulatory Pathway
Defined
Tutelix First In
Human Cohort 1
Read-out
Quality & Supply
Agreement
Execution
US/AU Capital
Raise
Tutelix Primary End
Point for Cohort 2
Pivotal Clinical
Trial Initiation
Henry Schein Supply &Licensing
Agreement Execution
Data read-out from
the FDA study
FDA
Clearance
FDA Submission
9 months after ASX listing - Efficient use of Funds and Strong Cash Position
Near Term Milestones
Working
Capital
$23.0m
$(2.0m)
$25.0m
Current assets
Strong cash on hand position of $21.6million
Operating cash flow at $~2.2m per quarter
AUD
$ million
H1 FY25
$0.21m
H1 FY26
$0.27m
Overhead spend per employee *at
$0.27million reflecting capital light model
AUD $ million
* Overhead spend per employee excls Direct R&D project opex
Current liabilities
H1 FY25
$0.46m
H1 FY26
$1.8m
Revenue and other income
+291% vs H1 Fy25, driven by
IGPgrant and R&D tax
incentive to fuel growth
+291% vs H1 FY25
FY2026 FY2027
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
Cohort 2
Commenced
Year 1 Follow up for
Cohort 1 results
published
TetraDerm Cohort
3 Initiation
(Major Surgeries)
ONCOLOGY
DENTAL
Master Partnership
Agreement Execution
Supply and Licensing
Agreement Execution
FDA
Clearance
FDA Submission
New Facility Signed
and production begins
IGP Grant
Board
Restructure
ISO13485
surveillance
Audit
MDSAP
Stage 1
Audit
Primary End-
point Cohort 2
FDA Pre-submission
& Regulatory Pathway
BioOptix Licensing
Agreement
US / AU
Capital Raise
Preclinical Data
Read-out
Strategic Global
Partnership
FDA Pre-submission &
Regulatory Pathway
FDA Pre-submission/
Regulatory Pathway
Defined
Tutelix First In
Human Cohort 1
Read-out
Quality & Supply
Agreement
Execution
US/AU Capital
Raise
Tutelix Primary End
Point for Cohort 2
Pivotal Clinical
Trial Initiation
Henry Schein Supply &Licensing
Agreement Execution
Data read-out from
the FDA study
FDA
Clearance
FDA Submission
New Facility Signed
and production begins
IGP Grant
Board
Restructure
ISO13485
surveillance
Audit
MDSAP
Stage 1
Audit
BioOptix Licensing
Agreement
US / AU
Capital Raise
Preclinical Data
Read-out
Strategic Global
Partnership
FDA Pre-submission &
Regulatory Pathway
FDA Pre-submission/
Regulatory Pathway
Defined
Tutelix First In
Human Cohort 1
Read-out
Quality & Supply
Agreement
Execution
US/AU Capital
Raise
Tutelix Primary End
Point for Cohort 2
Pivotal Clinical
Trial Initiation
Henry Schein Supply &Licensing
Agreement Execution
Data read-out from
the FDA study
FDA
Clearance
FDA Submission
Commercial Milestones & Partnerships
Relentless Execution
Global Distribution and Supply Agreement with the world’s largest provider of
healthcare solutions for dental market launch.
R&D agreement with the world’s biggest ophthalmology technology company
to develop next generation ophthalmic devices.
Tutelix successfully completed its Series A capital raise to expedite clinical trial
and launch in the US - supported by US clinicians.
FY2026 FY2027
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
Cohort 2
Commenced
Year 1 Follow up for
Cohort 1 results
published
TetraDerm Cohort
3 Initiation
(Major Surgeries)
ONCOLOGY
DENTAL
Master Partnership
Agreement Execution
Supply and Licensing
Agreement Execution
FDA
Clearance
FDA Submission
Primary End-
point Cohort 2
FDA Pre-submission
& Regulatory Pathway
TTX has now excitingly announced a new US partnership in precision medicine
with Superpower Health.
Technical & Clinical Milestones
#anchoredbyscience
Relentless Execution
FDA studies progressing as planned, 100% pass rate for all
in vivo implantations safety and performance studies.
Progression of TetraDerm clinical trial and achieving 1 year follow up
data from the cohort 1 of the trial with indications of efficacy.
0 13
3 MONTHS
12 MONTHS
1.8
1.1
INTACT
SKIN
VISIBLE
SCARRING
0 13
Initiation and successful progression of
prostate spacer trial, 15 patients
treated with solid indications of
performance.
FY2026 FY2027
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
Cohort 2
Commenced
Year 1 Follow up for
Cohort 1 results
published
TetraDerm Cohort
3 Initiation
(Major Surgeries)
ONCOLOGY
DENTAL
Master Partnership
Agreement Execution
Supply and Licensing
Agreement Execution
FDA
Clearance
FDA Submission
New Facility Signed
and production begins
IGP Grant
Board
Restructure
ISO13485
surveillance
Audit
MDSAP
Stage 1
Audit
Primary End-
point Cohort 2
FDA Pre-submission
& Regulatory Pathway
BioOptix Licensing
Agreement
US / AU
Capital Raise
Preclinical Data
Read-out
Strategic Global
Partnership
FDA Pre-submission &
Regulatory Pathway
FDA Pre-submission/
Regulatory Pathway
Defined
Tutelix First In
Human Cohort 1
Read-out
Quality & Supply
Agreement
Execution
US/AU Capital
Raise
Tutelix Primary End
Point for Cohort 2
Pivotal Clinical
Trial Initiation
Henry Schein Supply &Licensing
Agreement Execution
Data read-out from
the FDA study
FDA
Clearance
FDA Submission
Relentless Operational Execution
Near Term Milestones
Australian Federal Government industry grant, $3.3m to co-fund the
planned development activities.
Completed and successfully passed ISO13485 surveillance audit
with construction initiated in the new site for 10X expansion.
Peter Grey (Co-Founder of Zip) joined the board of directors
further strengthening the board to navigate highly regulated global
market.
Ongoing and meaningful disclosures to the market:
8
Technical and
Commercial Updates
15
Total Reports and
Market Updates
3
Clinical trial updates
and news
On-budget delivery of milestones and cash on hand $21.6m (from
$25m raised in IPO and $9m from pre-IPO).
FY2026 FY2027
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
Cohort 2
Commenced
Year 1 Follow up for
Cohort 1 results
published
TetraDerm Cohort
3 Initiation
(Major Surgeries)
ONCOLOGY
DENTAL
Master Partnership
Agreement Execution
Supply and Licensing
Agreement Execution
FDA
Clearance
FDA Submission
New Facility Signed
and production begins
IGP Grant
Board
Restructure
ISO13485
surveillance
Audit
MDSAP
Stage 1
Audit
Primary End-
point Cohort 2
FDA Pre-submission
& Regulatory Pathway
BioOptix Licensing
Agreement
US / AU
Capital Raise
Preclinical Data
Read-out
Strategic Global
Partnership
FDA Pre-submission &
Regulatory Pathway
FDA Pre-submission/
Regulatory Pathway
Defined
Tutelix First In
Human Cohort 1
Read-out
Quality & Supply
Agreement
Execution
US/AU Capital
Raise
Tutelix Primary End
Point for Cohort 2
Pivotal Clinical
Trial Initiation
Henry Schein Supply &Licensing
Agreement Execution
Data read-out from
the FDA study
FDA
Clearance
FDA Submission
4
Partnership and
commercial validation
Patient out-
of-pocket
Patient out-
of-pocket
Reimbursed
(US)
60-70% ~75-85% ~60-70%
Payer
Expected GM for
TTX
70-80% ~80-90%
Expected GM for
Partner
1
~70-80%
TAM US$3.4bn
TAM US$1.3bn US$2.1bn
We verify the final end
user pricing and the gross
margin targets for our
strategic partners before
progressing
Bone
Regeneration
1. Weighted Blended Standard Gross Margin
Not simply a science experiment. Tetramatrix provides real world economics.
TM
Tissue Healing
Tissue Spacing
Unit Economics
Manufacturing POD
Our manufacturing process is:
Highly Scalable with supply chain security
Our manufacturing process is designed in a ‘POD’ framework whereby every POD can operate
independently
The POD has a foot print of 200 sqm, and can be replicated multiple times without our facility floorspace
Allows multiple X increases in the production capacity in a fast and controlled manner
De-risked
We have previously increased our production yield per batch from laboratory scale (10 g per
batch) to a commercial scale (1.2kg) through multiple cycles of process optimisation and scale up
The production process is not labour-intensive and requires only off-the-shelf equipment
All raw materials are catalogue products and easily accessible from multiple suppliers, de-risking any
supply chain risk
A new, larger site in Alexandria, Sydney has been identified with the lease now executed and signed
Advanced manufacturing and operations
We have established advanced manufacturing in Sydney. To meet growing demand, a new
lease agreement has been executed and the new facility is planned to be commissioned in
2026, with a modular design to allow us to quickly scale as needed.
Manufacturing
Manufacturing
37 m
Finished Goods
Pods (x6)
Auxiliary
Pods (x2)
Office #3
Synthesis Pods (x5)
61
m
We have executed a lease agreement (10 + 5 Years)
and have secured relevant approval to start
construction at the site. The project in on track to
move the headquarter to the new site in FY26 and
the first formal production in FY27.
The New TTX HQ and Manufacturing campus construction on track
$25.0m
Manufacturing
upscale
$2.2m in H1Fy26,
22% of $11m UOF
Maunfacturing
total UOF
$11.0 m
Spend
to date
22%
TTX continues to evolve and plans to relentlessly execute into FY27 and beyond
Near Term Milestones
US/AU Capital
Raise
Initiation Cohort 3
ORTHOPAEDIC
OPHTHALMIC
SURGICAL
SITE MGMT
OPERATIONS
ONCOLOGY
DENTAL
Present FY2028
FY2027
FDA Clearance
First Final Product
Dispatch to HS
TGA
(Australian Market Launch)
Market Seeding for
Portfolio Expansion
Supply and Licensing
Agreement Execution
FDA Clearance
First Final Product
Dispatch to US Partner
Market Seeding for
Portfolio Expansion
Pivotal Trial Initiation
Australia
IDE Approval from
FDA for the US Arm of
the Pivotal
Primary End Point Data
Read-out Pivotal
Portfolio
Expansion
Preclinical Data Read-
out
FDA Pre-submission &
Regulatory Pathway
Interim Technical
Reporting with Alcon
FDA engagement for
IDE approval for US
Pivotal Trial
AU Pilot
Trial
TetraDerm Cohort 3
Initiation
(Major Surgeries)
Primary End-point
Cohort 2
FDA Pre-submission &
Regulatory Pathway
Year 1 Data-readout
from Cohor 2
MDSAP Stage 2
Audit
The New Site Head
Quarter Opening
MDSAP Stage 1
Audit
First Product Dispatch
from the New Campus
PRECISION
MEDICINE
First Polymer
Dispatch (STEPP)
First License
Revenue
STEPP Sale
Revenue
GLP-1 Data
Point 1
Portfolio
Expansion
ASX: TTX ABN: 72 607 771 077
APPENDIX
Tegenix | Dental Bone Graft
Flowable
Carrier
Bone Graft
In situ
Mixing
Mouldable and
shapable putty
Press-fit
Gentle press-fit into the
site and adherence without
primary closure
Easy to handle and
easy to manipulate
Amenable to different graft
particles and easy to mix
Partners
TegenEOS | Orthopaedic Bone Graft
Fills the void and
keep grafts
geometrically in
place
Tegenix resorption
allowing cell and blood
vessel ingrowth for
effective activation of
grafts
Expedited healing
Flowable mixture of
Tegenix and bone graft
material
Supply Agreement in FY26
FDA Clearance in FY26
Market Launch in FY26 in the US
Key Dates From the Prospectus
Supply Agreement in FY26
FDA Clearance in FY26
Market Launch in FY27 in the US
A universal enabling solution to simplify complex oral & dental procedures
Bone Regeneration - Dental & Orthopaedic
Partners
Currently Under Due Diligence
with multiple key players
Key Dates From the Prospectus
On-track commercial launch in 2026 as outlined in the prospectus
Commercial launch of Tegenix is
progressed as planned. Global HS
as well as the Australian arm are
engaged and multiple strategies in
place to maximise in market
success of the product.
Supply and Distribution
Agreement
Generation 1
First product sale USA
Generation 1 Market
Launch
(AU)
Generation 2 (dry powder)
Development
FY27
Generation 1 Market
Seeding (US/AU)
FY28
Gen 2 Market
Expansion
Gen 3 (pre-mixed
format) Development
FY29
Gen 3 Approvals
(CE/ FDA)
Polymer supply to
tissue banks as raw
material
Optimised Global
Market Presence
Tegenix | Dental Bone Graft
Tegenix
Strategic Realignment - Prioritising Highest-Return Partnerships
One of our leading potential ortho partners recently made a strategic shift in product and corporate strategy. This shift
meant our long term ortho stability may have been challenging (specifically in the US shift to day-surgery clinics) which
would have increased integration complexity and execution risk over the long term. As such, we have deliberately chosen
to refocus our due diligence efforts on 2 other leading ortho partners - the advantage of our partnership model.
Strategic pivot in partnership assessment and still on-track for commercial launch in FY27 as outlined
in the prospectus
On-track for commercial launch in 2026 as outlined in the prospectus
TegenEOS | Orthopaedic Bone Graft
Two partners now in late stage due diligence
Partner A: Global market leader with extremely strong enterprise channels and strong revenue growth (in a flat market), offset by
legacy integration complexity.
Partner B: High-growth global scaler with flexible commercial terms and co‑innovation upside, offset by execution risk if priorities
shift.
Either partner materially strengthens the TTX portfolio and we continue to progress the discussions for final decisions on track for 2026.
Injection to the space
between prostate/
rectum
Space generation to reduce
side effects to rectum during
radiation
Safe & easy to use solution for more effective & simpler spacing in radiation oncology
Key features
Tutelix is intended for use as a spacer to reduce side effects to surrounding tissue during radiation therapy to treat prostate cancer. It is easily injected
and is gradually resorbed by the body and excreted over time (12 weeks) without harm to any internal organs
TM
1
2
3
Procedure Optionality
A water-based solution makes the product amenable to
single injection after hydrodissection OR as multiple gradual
injections, two commonly used techniques.
Visible to physicians under both CT-scan
and ultrasound
In contrast to incumbent products, the product is visible
under ultrasound during administration and under Computed
Tomography without enhancement which allows for a safer,
simpler, more accurate and cost-effective outcome when
delivering radiotherapy.
Simple to adjust (+/- volume)
Activated organically by body temperature, the solution
transitions into a hydrogel. The hydrogel is smooth, flowable
and can be immediately reversed with cold-saline. The
hydrogel breaks down to non-toxic components and
bioresorbs within 3 to 6 months completely.
| Tissue Spacing - Oncology
Tutelix progressed first
Share your feedback
Discover